Enroll in My Home to simplify finding a doctor and sheduling an appointment. Let's start!
By selecting "I Agree" or "Create Account" and clicking the box "I AGREE" below, you acknowledge and agree that you have read, understood and accepted the terms of service at the hyperlink below:
Legal and Privacy Notices
St. Joseph's Awards
St. Joseph's Executive Leadership
History of St. Joseph's
St. Joseph's Mission, Vision and Values
Research and Education
Press Center and News
The findings, published in the Feb. 14 edition of The Lancet Oncology, show that selumetinib targets a mutation in the MAPK pathway for patients with lowgrade serous carcinoma, allowing for treatment on previously chemoresistant tumors.
“This is a potentially important breakthrough for the Gynecologic Oncology Group,” said John Farley, MD, a gynecologic oncologist in the Division of Gynecologic Oncology and the Department of Obstetrics and Gynecology at the Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, a Dignity Health Member.
The Gynecologic Oncology Group is a non-profit international organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies.
Dr. Farley is part of the University of Arizona Cancer Center at St. Joseph’s and is board certified in obstetrics and gynecology with a subspecialty certification in gynecologic oncology. He is a retired decorated Army colonel who completed a residency in obstetrics and gynecology and a fellowship in gynecologic oncology at Walter Reed Army Medical Center. He is the first author on this study.
This study was initially developed in 2007, with 52 patients enrolled for the Phase II clinical trial between December 2007 and November 2009. Patients were given 50 milligrams of selumetinib orally twice daily. Of those participants, eight had a measurable decrease in tumor size, seven had partial responses and 34 patients saw their tumors stabilize. The findings suggest that inhibitors of the MAPK pathway warrant further investigation in patients with low-grade ovarian cancer.
“There just aren’t very good treatments for low-grade ovarian cancer, so this discovery opens up a lot of new exciting possibilities for us,” Dr. Farley said. He added that Phase III of this trial is scheduled to begin in the next few weeks, with that trial to be the “definitive test” before the treatment becomes available to the general population.
This study is registered with ClinicalTrials.gov, number NCT00551070.
The University of Arizona Cancer Center is the only National Cancer Institute-designated Comprehensive Cancer Center headquartered in Arizona. The UACC is supported by NCI Cancer Center Support Grant number CA023074. With primary locations at the University of Arizona in Tucson and at St. Joseph’s Hospital and Medical Center in Phoenix, the Cancer Center has more than a dozen research and education offices in Phoenix and throughout the state and 300 physician and scientist members work together to prevent and cure cancer. For more information, go to http://www.arizonacancercenter.org
Located in the heart of Phoenix, Ariz., St. Joseph's Hospital and Medical Center is a 607-bed, not-for-profit hospital that provides a wide range of health, social and support services with special advocacy for the poor and underserved. St. Joseph’s is a nationally recognized center for quality tertiary care, medical education and research. It includes the internationally renowned Barrow Neurological Institute, the Heart & Lung Institute, the Muhammad Ali Parkinson Center, and a Level I Trauma Center verified by the American College of Surgeons. U.S. News & World report routinely ranks St. Joseph’s among the best hospitals in the United States for neurology and neurosurgery.